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Abstract
We are daily exposed to a large number of pharmacological drugs,  environmental
pollutants, and natural toxins, which represent a potential toxic insult. The organism
possesses a sophisticated system of detoxification particularly expressed in the liver,
intestine, and kidney. This system consists of intracellular biotransformation enzymes
that convert the toxins into more hydrophilic derivatives followed by their elimination
through membrane transporters.  Multidrug resistance-associated protein  2  (MRP2,
ABCC2) is an important member of the ATP-binding cassette (ABC) superfamily of
transporters localized at the apical membrane of polarized cells, such as hepatocytes,
enterocytes, and renal tubular cells. MRP2 is proposed as a major actor in the elimination
of endo- and xenobiotics, mainly conjugated with glucuronic acid, glutathione, and
sulfate.  The  small  intestine  and  the  liver  constitute  relevant  detoxification  organs
expressing MRP2 and therefore preventing absorption and promoting the hepatobiliary
clearance  of  xenobiotics.  MRP2  expression  and/or  function  can  be  modulated  by
therapeutic drugs, herbal products, dietary compounds, and environmental pollutants.
Consequently, MRP2 modulation could cause changes in tissue exposure, with potential
toxicological and pharmacological consequences. This chapter reviews the information
available on the role of hepatic and intestinal MRP2 in detoxification processes, and their
regulation by xenobiotics, considering in particular its toxicological relevance.
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1. Introduction
1.1. Detoxification of xenobiotics
Most organisms are daily exposed to a large number of different xenobiotics, such as thera-
peutic drugs, environmental pollutants, and natural toxins. The major routes of exposure to
these chemicals comprise incorporation with the diet, inhalation or absorption through the
skin. Preservation of health depends largely on the body's ability to eliminate these harmful
substances. In this regard, the organism possesses a sophisticated system of detoxification
mainly expressed in organs such as the liver, intestine, and kidney. The detoxification process
consists of intracellular biotransformation enzymes that neutralize the toxins and membrane
transporters for their subsequent elimination from the cell. The biotransformation process is
carried out by the same biochemical machinery that metabolizes endogenous compounds,
often of similar chemical structure. Even though a compound can be excreted without
undergoing any change, it is usually converted by biotransformation enzymes into a more
hydrophilic derivative prior to elimination. The biotransformation reactions are carried out by
phase I enzymes such as cytochrome P450 (CYP) members and by phase II conjugating
enzymes such as glutathione S-transferase (GST; EC 2.5.1.18), UDP-glucuronosyltransferase
(UGT; EC 2.4.1.17), and sulfotransferase (SULT; EC 2.8.2.) [1, 2]. Phase I enzymes usually act
in tandem with phase II enzymes, which ultimately results in incorporation of anionic groups
into the xenobiotic molecule. The hydrophilic derivatives can be excreted from the cells by
phase III or membrane transport systems, with the anionic groups acting as affinity markers for
a series of transporters of the multidrug resistance-associated protein (MRP) family. These
proteins are members of the ATP-binding cassette (ABC) drug efflux transporters and mediate
the active extrusion of biotransformation products for their subsequent elimination from the
body [1, 2]. Direct elimination of xenobiotics without suffering any biotransformation is also
possible and is denominated “phase 0 metabolism” [3].
What follows is a description of the role of the multidrug resistance-associated protein 2
(MRP2, ABCC2) as an important component of the ABC family involved in xenobiotic
disposition by liver and intestine.
1.2. Multidrug resistance-associated protein 2 and its role in the detoxification of xenobiotics
MRP2 structure consists of a large core segment, containing two cytosolic nucleotide-binding
domains (NBDs), two membrane-spanning domains (MSDs), and a linker segment L1, shared
by other ABC members. Additionally, MRP2 contains a third NH2-terminal membrane-
spanning domain MSD0, also called terminal transmembrane domain, with five transmem-
brane helices resulting in an extracellular NH2-terminus and an intracellular linker segment 0
(L0) (Figure 1) [4]. MRP2 is characteristically expressed at the apical membrane of polarized
cells such as hepatocytes, enterocytes, and renal tubular cells [4–6], where it plays a primary
role in the elimination of specific compounds. Particularly, the highest concentration of this
transporter is found in the liver and intestine [7], two organs playing a prominent role in
xenobiotic detoxification commonly known as “first-pass metabolism and clearance”. Protein
expression of MRP2 is highest in enterocytes of the proximal small intestine, decreasing in
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direction to the terminal ileum [8], gradient shared with the expression of phase II metabo-
lizing enzymes such as GST and UGT [9, 10], thus suggesting that metabolism and transport
processes may act coordinately. In the liver, the major biotransformation organ, MRP2 is
abundantly expressed in the bile canalicular membranes of the hepatocyte [11], where it plays
a role in bile formation through secretion of endogenous substrates such as glutathione (GSH)
and glutathione conjugates. Canalicular MRP2 also constitutes the main route of elimination
of xenobiotics conjugated with GSH, sulfate or glucuronic acid [12]. Similarly, immunohisto-
chemical analysis in normal rat liver demonstrated that UGTs and rMrp2 are localized in the
same regions [13, 14], also indicating that they may work in cooperation. MRP2 in either
localization contributes significantly to disposition of potentially harmful compounds thus
decreasing their toxicity.
Figure 1. (A) Molecular structure of MRP2/ABCC2. MSDs: membrane-spanning domains; NBDs: nucleotide-binding
domains; L0: linker segment 0. (B) Coordinated action between phase II metabolizing enzymes and MRP2 in the enter-
ocyte. Hydrophobic xenobiotics (X) may enter the cell by diffusion through the apical membrane of the enterocyte. Af-
ter that, they may suffer metabolic phase I reaction by cytochrome P450 and/or subsequent conjugation by phase II
enzymes, such as UDP-glucuronosyltransferase (UGT) localized in the endoplasmic reticulum or glutathione S-trans-
ferase (GST) or sulfotransferase (SUL) localized in the cytosol. In the phase III, the more hydrophilic metabolites (Y)
may be actively secreted into the intestinal lumen by MRP2. (C) Coordinated action between phase II metabolizing en-
zymes and MRP2 in the hepatocyte. Here, hydrophobic xenobiotics (X) enter the cell through the basolateral pole of
the membrane in the hepatocyte. After conjugation by phase II metabolizing enzymes, the final product (Y) may be
secreted into bile by MRP2.
Selected substrates of MRP2 are included in Table 1. Studies using Groningen Yellow (GY)/
TR- Wistar [15, 16] or Eisai hyperbilirubinemic rats (EHBR) [17] that are rMrp2 deficient as
a result of mutations leading to premature stop codons have helped to identify transporter
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substrates initially. Interestingly, ingredients of our daily diet are substrates for MRP2. That
is the case of the tea component epicatechin, the dietary supplement chrysin [18, 19], and
the meat-derived dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
(PhIP) [20]. Finally, it is important to emphasize that there are MRP2 substrates which influ-
ence transporter expression thus influencing its own bioavailability. That is the case, for ex-
ample, of tamoxifen [21].
Endogenous compounds       Exogenous compounds
Glutathione
Bilirubin glucuronides
Conjugated bile salts
Leukotrienes C4, D4, E4
Steroids
(17β-glucuronosyl estradiol)
Triiodo-L-thyronine
ethinylestradiol-3-O-glucuronide
Anticancer drugs: doxorubicin, epirubicin, etoposide, irinotecan, methotrexate,
mitoxantrone, cisplatin, tamoxifen, vincristine, vinblastine, camptothecin
Antibiotics: ampicillin, azithromycin, cefodizime, ceftriaxone, grepafloxacine,
irinotecan
HIV drugs: adenovir, cidofovir, indinavir, lopinavir, nelfinavir, ritonavir,
saquinavir
Other drugs:genistein-7-glucoside, p-aminohippurate, olmesartan, phloridzin,
pravastatine, quercetin 4′-β-glucoside, temocaprilate, conjugates of
acetaminophen, indomethacin, phenobarbital, sulfinpyrazone.
Toxicants: S-glutathionyl-2,4-dinitrobenzene, S-glutathionyl ethacrynic acid,
ochratoxin A, 2-amino-1-methyl-6-phenylimidazol[4,5-b]pyridin, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-buta-nol, α-naphtylisothio-cyanate,
heavy metal complexes (arsenic glutathione, Sb, Zn, Cu, Mn, Cd)
Dyes: fluo-3, carboxydichloro fluorescein, sulfobromophthalein
Flavonoids: epicatechin, chrysin
Table 1. Selected MRP2 substrates.
2. Regulation of expression and activity of MRP2 by xenobiotics
Expression of MRP2 can be regulated at different levels [22], which can be grouped in two
main categories: (i) transcriptional level, implying changes in mRNA synthesis rate, or (ii) post-
transcriptional level, comprising complex processes involving or not changes in MRP2 mRNA
levels. Regarding the transcriptional regulation, the MRP2 promoter contains a number of
binding sites recognizing a variety of transcription factors, which in turn can be activated by
either endo- or xenobiotics [23, 24]. Thus, a wide variety of drugs, environmental pollutants,
and natural toxins behave as ligands of transcription factors/nuclear receptors such as
farnesoid X-activated receptor (FXR), pregnane X receptor (PXR), liver X receptor α (LXRα),
and constitutive androstane receptor (CAR), to ultimately induce the synthesis of MRP2
mRNA [25]. They modulate MRP2 transcriptionally through binding to the response element
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ER-8, which extends from −401 to −376 bp of the MRP2 promoter [25]. Additionally, the study
of MRP2 promoter identified binding sites for other transcription factors such as the nuclear
factor-erythroid 2-related factor-2 (Nrf2), the peroxisome proliferator-activated receptor alpha
(PPARα), CCAAT/enhancer-binding protein-β (C/EBPβ), and hepatic nuclear factors (HNFs),
which can also influence the MRP2 expression at the transcriptional level. Finally, a particular
transcriptional regulation involves the intracellular nucleotide cyclic adenosine monophos-
phate (cAMP) pathway, likely triggered by xenobiotics acting predominantly through binding
to plasma membrane receptors. This was so far demonstrated in the intestine [26], where the
treatment of Caco-2 human intestinal cells with the membrane-permeable analogue dibutyryl
cAMP or the adenylyl cyclase activator forskolin led to a significant induction in hMRP2
protein and mRNA expression. Reporter gene and chromatin immunoprecipitation assays
performed in this same study showed an increased binding of the transcription factors c-JUN
and activating transcription factor-2 (ATF2) to a regulatory region containing activator
protein-1 (AP-1) and cAMP response element (CRE) binding sites within the MRP2 promoter.
On the other hand, post-transcriptional MRP2 regulation can involve the dynamic endocytic
retrieval and exocytic insertion of this transporter between the canalicular membrane and an
intracellular pool of vesicles [27]. A variety of signal transduction pathways involving the
activation of the mitogen-activated protein kinases (MAPK) A and C take part in these events
[27–29]. Also, mRNA splicing may account for post-transcriptional regulation. As an example,
alternative splicing of hMRP2 mRNA has been shown to be a cause underlying Dubin–Johnson
syndrome as a consequence of synthesis of nonfunctional protein [30, 31]. Additionally, MRP2
can be translationally modulated. In this regard, Jones et al. [32] observed that under certain
situations rMrp2 protein in rats is modified without changes in mRNA levels. This is not just
attributed to a modified rate of protein degradation but to the presence of several rMrp2
transcription initiation sites in the 5' untranslated region [7, 33]. The alternative use of these
sites leads to the production of different rMrp2 mRNAs with differential translational
efficiency.
What follows is a description of the regulatory properties of MRP2 as an important component
of the ABC family in liver and intestine. The effects of xenobiotics on MRP2 expression and
activity were particularly considered. Transcriptional and post-transcriptional regulations
were described separately.
2.1. Transcriptional regulation
Several xenobiotics including therapeutic drugs, environmental pollutants, and natural toxins
have shown to activate different transcription factors and nuclear receptors thus exhibiting
the potential of increasing MRP2 expression [34]. However, not all xenobiotics induce the
expression of MRP2. Indomethacin, a nonsteroidal anti-inflammatory drug, reduced the
expression of rat rMrp2 at the mRNA and protein levels in the liver [35]. This reduction was
associated with a diminished mRNA expression of the hepatic nuclear receptors CAR, FXR,
PXR, retinoic acid receptor α (RARα), and retinoid X receptor α (RXRα). This down-regulation
of nuclear receptors is consistent with observations in endotoxin-treated rats that also proved
to cause rMrp2 down-regulation at the transcriptional level [36, 37]. Intestinal injury caused
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by indomethacin can increase endotoxin levels in portal blood [38], which in turn induces
several immune responses and oxidative stress, as shown by the reduced levels of hepatic GSH
and increased levels of nitric oxide (NO) and nitrosothiols in portal blood [35]. In this regard,
El Kasmi et al. demonstrated that dextran sulfate sodium-induced intestinal injury also down-
regulates hepatic mMrp2 expression in mice liver and that the intestinal microbiota and TLR4
(Toll-like receptor 4) are involved in this effect [39]. In addition, it was shown that mice with
intestinal injury that received soy oil-based parenteral nutrition containing phytosterols
exhibited an exacerbated decrease in mMrp2 mRNA levels. The phytosterol stigmasterol was
at least partially involved and associated with increased levels of interleukin 6 (IL-6) mRNA
and reduced levels of FXR mRNA in liver [39].
In contrast to indomethacin, several drugs are able to induce the expression of MRP2. For
example, spironolactone (SL), a drug used to treat patients with edema and ascites, has been
shown to increase bile flow in rats due to the up-regulation of rMrp2 at the transcriptional
level, probably in response to increased PXR levels [40]. This up-regulation in rMrp2 resulted
in increased efflux activity of the model substrate of rMrp2 dinitrophenyl-S-glutathione (DNP-
SG) in vitro. These findings were in accordance with observations in patients exhibiting
increased clearance of drugs co-administered with SL [41, 42]. Benznidazole (BZL), a nitroi-
midazole administered for treatment of Chagas disease, was also shown to induce rMrp2
protein expression [43] in rats. This induction is presumably mediated by PXR, since knock-
down of the nuclear receptor in the hepatic cell line HepG2 prevented the induction of hMRP2
by this drug [44]. The antituberculosis agents rifampicin and isoniazid that cause liver injury
also up-regulate hepatic rMrp2 protein expression in rats [45]. Interestingly, monoammonium
glycyrrhizin, commonly present in Chinese herbal formulas used for hepatic protection,
prevented such increases in rMrp2 expression. In addition rifampicin and isoniazid increased
lipid peroxidation and GSH levels in hepatic tissue, indicating the presence of oxidative stress,
which was also prevented by monoammonium glycyrrhizin.
Acetaminophen (APAP) represents one of the most common over-the-counter drugs, used as
an effective and safe analgesic and antipyretic. Nevertheless, APAP overdose is very frequent
and associated with severe liver injury. Although the mechanism underlying APAP toxicity is
not completely understood, the CYP-biotransformation product N-acetyl-p-benzoquinone
imine (NAPQI) was described as a mediator of APAP toxic effects since it promotes GSH
depletion and binds itself to cellular proteins [46]. APAP phase II metabolites resulting from
conjugation with glucuronic acid and sulfate are known MRP2 substrates. Similarly, MRP2
transports the GSH conjugate of NAPQI, thus contributing to reduce the toxic burden exerted
by APAP. In this regard, the administration of a single hepatotoxic dose of APAP to Wistar rats
resulted in an increase in rMrp2 expression in liver plasma membranes [47]. In a similar study,
an induction hepatic mMrp2 following Nrf2 activation was demonstrated in mice, clearly
suggesting the presence of an adaptive mechanism to the APAP-triggered injury [48, 49]. In
line with these observations, therapeutic activation of Nrf2 has been proposed as a possible
strategy to ameliorate APAP-associated hepatotoxicity [50–52]. Nrf2 bears a special toxicolog-
ical relevance due to its activation by pro-oxidant compounds and reactive metabolites usually
associated with situations of drug overdose or exposure to environmental toxicants. Under
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homeostatic conditions, Nrf2 is sequestered in the cytosol by the Kelch-like ECH-associated
protein 1 (Keap1) which promotes Nrf2 ubiquitination and proteosomal degradation. Upon
an oxidative stimulus, it takes place a modification in the oxidation status of particular cysteine
residues in the Keap1 molecule leading to Nrf2 dissociation and migration to the nucleus where
it binds to antioxidant response elements (ARE) within the promoters and activates the
transcription of target genes [53] including antioxidant and GSH synthesis enzymes and also
drug transporters like MRP2 [54]. Management of Nrf2 activation could be applied to other
cases of oxidative stress-associated hepatic injury. For instance, the Nrf2 activator N-acetyl-
cysteine was described to ameliorate the rMrp2 down-regulation exerted by the pro-oxidant
phytochemical timosaponin A3 [55]. Similarly, other Nrf2 activators are being tested in clinical
trials for the treatment of hepatic and extrahepatic diseases [53].
Environmental pollutants such as arsenite significantly increased rMrp2 protein expression in
rat liver after 2 weeks of exposure. Longer exposure treatment (4 or 6 weeks) also increased
rMrp2 expression but to a lesser extent [56]. Arsenite not only regulates Mrp2 but is also an
MRP2 substrate, so transporter induction may help to counteract the toxic effects of arsenite
in the liver. In agreement with this, arsenite content in bile decreased with the exposure time
in the same manner as rMrp2 protein induction. Lipid peroxidation was increased and GSH
peroxidase activity was reduced in the liver at 4 and 6 weeks of arsenite exposure, indicating
a probable effect of oxidative stress in attenuating hepatic rMrp2 induction. This regulation of
Mrp2 may explain the dual effects reported for arsenite exposure [57].
The T-2 mycotoxin is commonly found in different crops. Prolonged exposure (3 weeks) of
poultry to T-2 reduced cMrp2 mRNA expression in the liver of broiler chickens [58]. Although
the authors suggest that PXR may be involved in the down-regulation observed, no studies
were conducted to prove that. The organochlorine pesticides 2,4'-dichlorodiphenyltrichloro-
ethane (DDT), 4,4'-DDT, chlordane, heptachlor, dieldrin, and lindane, highly resistant to
degradation, were shown to increase hMRP2 mRNA in HepaRG cells after a 48-h exposure
[59]. This regulation could be mediated by PXR, since this nuclear receptor expression was
increased in human hepatocytes after treatment with chlordane, dieldrin, and endosulfan [60].
Bisphenol A (BPA) is a typical contaminant of food, water, and air. A study evaluating the
association between the expression of drug transporters in fetal liver and BPA exposure
showed a positive correlation between BPA levels and hMRP2 expression. A similar correlation
was described between BPA levels and Nrf2 expression, suggesting also a mediation of this
transcription factor in the hMRP2 regulation by BPA and agreeing well with a previous report
showing Nrf2 activation by BPA in vitro [61, 62].
Transcriptional regulation of MRP2 by xenobiotics was also demonstrated in extrahepatic
tissues like the small intestine. An example of therapeutic drugs affecting MRP2 gene expres-
sion is rifampicin, a well-known PXR agonist which has been demonstrated to increase hMRP2
expression and activity in healthy volunteers. Fromm et al. reported an up-regulation of
hMRP2 mRNA and protein in duodenal biopsies [63]. Later, Oswald et al. showed the impact
of this regulation on oral availability and efficacy of the coadministered drug ezetimibe [64].
The same inducing effect was reported using the human-derived cell line LS180 [65]. Similarly,
carbamazepine is another PXR agonist [66] shown to increase hMRP2 mRNA and protein levels
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in human healthy volunteers and also to reduce intestinal absorption of the co-administered
MRP2 substrate talinolol [67].
Even though there are only few reports on drug–drug interactions associated with PXR-
dependent modulation of intestinal MRP2, many other agents have been shown to regulate its
expression via PXR. Pregnenolone-16α-carbonitrile, a synthetic steroid, induced mMrp2
mRNA expression in jejunum of C57BL/6 mice (200 mg/kg, i.p., 4 days). A concomitant up-
regulation of PXR mRNA was observed and the involvement of this nuclear receptor was
confirmed using PXR knockout mice [68]. The antiviral agents and PXR agonists efavirenz and
saquinavir [69] also up-regulated hMRP2 expression in LS180 cells [65, 70]. Since these drugs
are usually involved in long-term treatments, coadministration with MRP2 substrates could
result in unwanted drug–drug interactions. In the same human intestinal cell line, the effect
of the endothelin receptor antagonist bosentan [71] and the antineoplastic mitotane [72] was
demonstrated. They both exerted a significant hMRP2 induction concomitantly with PXR
activation at pharmacologically relevant concentrations.
In some studies, the increases in MRP2 expression were correlated experimentally with
increased transport activity. Examples of these drugs are BZL and SL, both PXR agonists.
Perdomo et al. reported an induction of rMrp2 protein in jejunum of BZL-treated rats (100 mg/
kg, i.p., 3 days) [43]. This change was accompanied with an increased efflux of DNP-SG to the
intestinal lumen. These results not only demonstrate higher secretion of rMrp2 substrates but
also strongly suggest a restriction in the absorption of xenobiotics incorporated luminally in
BZL-treated rats. Similarly, SL was demonstrated to increase serosal to mucosal transport of
DNP-SG well correlating with increased rMrp2 mRNA and protein expression in rat proximal
jejunum. The PXR antagonist ketoconazole was able to prevent this induction, suggesting
mediation by this nuclear receptor [73].
Cimetidine and quinidine have been shown to increase both hMRP2 and PXR expressions in
T84 cells [74]. Similarly, the anticonvulsant phenobarbital induced PXR mRNA and hMRP2
mRNA and protein at the same time in Caco-2 cells [75]. On the contrary, MRP2 expression is
down-regulated by drugs that decrease PXR expression. Haslam et al. reported such an effect
in T84 cells for the cholesterol-lowering drug atorvastatin and the anticancer agents topotecan
and irinotecan [74].
Xenobiotics can regulate expression of intestinal MRP2 interacting with nuclear receptors other
than PXR. That is the case of the bcl-2 inhibitor obatoclax, which at nanomolar concentrations
induced hMRP2 mRNA in LS180 cells through activation of the aryl hydrocarbon receptor [76].
Another example is the proteasome inhibitor bortezomib, which also increases hMRP2 mRNA
expression in SW-480 human cells [77]. Even though the mediator has still to be identified, the
transcription factor Nrf2 appears to be the main candidate considering its simultaneous up-
regulation and also the well-demonstrated relationship between MRP2 induction and Nrf2
activation in tissues like liver [49], kidney [78], and brain [79].
Among the natural compounds modulating intestinal MRP2, the isothiocyanates sulforaphane
(SF) and erucin (ER) were well studied. Derived from cruciferous vegetables, they have drawn
the attention of the researchers due to their anticancer properties [80]. After microarray studies,
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Traka et al. reported hMRP2 up-regulation in Caco-2 cells treated with SF (50 μM, 24 h) [81].
They confirmed this finding by RT-PCR analysis. Using the same model, Jakubíková et al.
showed a similar hMRP2 mRNA increase after treatment with SF and with ER (20 μM, 24 h)
[82]. This effect appears to be partly mediated by phosphoinositide 3-kinase (PI3K)/AKT,
considering the inhibition exhibited by the PI3K/AKT inhibitor LY294002. Later, in analogous
experimental conditions, Harris and Jeffery demonstrated an induction also at protein level
[83]. Considering that Nrf2 is activated by SF [84], this transcription factor may play a role in
MRP2 up-regulation.
Other naturally occurring xenobiotics found to modulate intestinal MRP2 are the polyphenols
quercetin and resveratrol (RES). The first one was demonstrated to up-regulate hMRP2 at
protein level in Caco-2 cells (50 and 100 μM, 72 h). A coordinated induction of the phase II
enzyme UGT1A6 was also observed, suggesting reduced absorption and enhanced secretion
of glucuronides at intestinal level [85]. Studies using RES have become of strong interest after
the increasing evidence regarding its beneficial health effects. A short time ago, RES ability to
down-regulate MRP2 at mRNA and protein levels has been proven in rat intestine and Caco-2
cells [86]. The functional impact was evaluated in the latter model by determination of
intracellular retention of the MRP2 substrate methotrexate (MTX). Treatment with RES
increased the accumulation of MTX, suggesting a suppressed efflux activity. Moreover, in an
attempt to clarify the mechanism, the authors found a concomitant inhibition of the insulin-
like growth factor receptor 1 (IGF-1R)/AKT/ERK signaling pathway.
2.2. Post-transcriptional regulation
As anticipated, post-transcriptional regulation of MRP2 activity may also occur in response to
exposition to xenobiotics. Faldaprevir is a drug used to treat patients with hepatitis C in spite
that it causes hyperbilirubinemia. Acute treatment of human and rat hepatocytes with
faldaprevir inhibited hMRP2-/rMrp2-mediated efflux of bilirubin glucuronides into bile [87].
This may partially explain the impaired bilirubin disposition by faldaprevir. However,
toxicology studies in monkeys and patients showed that the bilirubin accumulated during
faldaprevir treatment was mainly unconjugated, suggesting that the main cause is probably
inhibition of glucuronidation ather than excretion of the conjugated metabolites. Simeprevir,
another drug used to treat hepatitis, causes hyperbilirubinemia composed by conjugated and
unconjugated bilirubin, which supports an impaired hMRP2 efflux activity [88].
Ethynylestradiol (EE) and genistein (GNT) are estrogenic compounds of particular relevance
considering their oral incorporation as components of contraceptives formulations and soy-
derived food, respectively. Interestingly, they were demonstrated to regulate intestinal MRP2
at post-transcriptional level, although showing a noticeable dose and model dependence.
Thus, it was initially found that EE at a cholestatic dose (5 mg/kg b.w. day, for 5 consecutive
days, s.c.) down-regulates rMrp2 expression and function in rat proximal jejunum, without
changes in mRNA levels [89]. However, at pharmacological concentrations (0.5–5 pM) EE up-
regulates hMRP2 expression and activity in Caco-2 cells. This hMRP2 induction was estrogen
receptor β (ERβ)-mediated but not associated with changes at the mRNA level, thus suggesting
a post-transcriptional regulation [90]. The implication of ERβ in such kind of regulation is
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possible since it was reported to regulate miRNAs expression [91] which, in turn, can alter
hMRP2 expression [92]. Similarly, Caco-2 cells exposed to GNT (1 μM, 48 h) exhibited an
ERβ-mediated hMRP2 induction at protein level without changes in expression at the mRNA
level. This was associated with increased transporter activity and enhanced protection against
1-chloro-2,4-dinitrobenzene, an MRP2 substrate precursor [90]. GNT can also modulate MRP2
activity in an acute fashion, i.e., without changes in transporter expression. Some years ago, it
was reported that this isoflavone competitively inhibits hepatic rMrp2 in isolated and perfused
rat liver model [93]. In line with this result, Yokooji et al. demonstrated that GNT administered
intravenously reduced rMrp2-mediated secretion of irinotecan hydrochloride and its metab-
olites in rat liver and intestine [94].
The uricosuric drug probenecid represents another example of xenobiotics affecting intestinal
MRP2 activity without modifying MRP2 expression. Probenecid is a classical competitive
inhibitor of organic anions transport also used in the clinical practice to enhance plasma levels
of antibiotics. Although nonspecific, its inhibitory effect on intestinal MRP2 was clearly
demonstrated in rats [95] and in Caco-2 cells [90]. Nowadays, more potent and specific MRP
inhibitors like MK571 are preferred for characterization of transport specificity. Finally,
various members of the large family of nonsteroidal anti-inflammatory drugs are recognized
MRP2 modulators [96]. In intestine, indomethacin was shown to inhibit MRP2 and to increase
sulfasalazine transepithelial permeability, both in rat small intestine and in Caco-2 cell
monolayers [97]. In agreement with these findings, Caco-2 cells coincubated with indome-
thacin exhibited an increased permeability to the hMRP2 substrates fluvastatin [98] and
colchicine [99].
3. Conclusion
Although the organisms are permanently exposed to a wide range of xenobiotics such as
therapeutic drugs, environmental pollutants, and natural toxins, they possess a sophisticate
system of detoxification in which metabolizing enzymes and transport proteins play an
essential role. Evidence from in vitro and in vivo studies unambiguously demonstrates that
MRP2 is a crucial actor in protecting specific tissues from xenobiotic toxicity. It is noteworthy
that MRP2 also plays a crucial role in elimination of endogenous metabolites. A list of relevant
and well-recognized substrates of MRP2 is presented in Table 1. Two relevant tissues express-
ing MRP2 are the liver and the small intestine. It should be noted that other participants not
contemplated in this review, such as a bunch of metabolizing enzymes as well as members of
the family of ABC transporters different from MRP2, are additionally involved in xenobiotic
detoxification.
Expression and activity of MRP2 can be modulated at both transcriptional and post-transcrip-
tional levels. The nuclear receptor PXR plays a major role in transcriptional regulations. PXR
functions as sensor for many agents and its activation leads to a coordinated response on
biotransformation enzymes and transport systems. Examples of these agents are rifampicin,
carbamazepine, pregnenolone-16α-carbonitrile, efavirenz, saquinavir, BZL, SL, etc. Other
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xenobiotics such as bortezomib, BPA, and sulforaphane regulate MRP2 as a result of the
interaction with Nrf2. Alternatively, regulation of MRP2 activity by xenobiotics can occur
without changes in transporter expression, as it was demonstrated to GNT. Finally, it is
important to note that regulation of MRP2 activity by therapeutic agents can result in changes
in their therapeutic efficacy or safety, or alternative in drug–drug interactions if other drugs,
substrates of MRP2, are simultaneously administered.
Abbreviations: ABC, ATP-binding cassette; AP-1, activator protein-1; APAP, acetaminophen;
ARE, antioxidant response elements; ATF2, activating transcription factor-2; BPA, bisphenol
A; BZL, benznidazole; C/EBPβ, CCAAT/enhancer-binding protein-β; cAMP, cyclic adenosine
monophosphate; CAR, constitutive androstane receptor; CRE, cAMP response element; CYP,
cytochrome P450; DDT, dichlorodiphenyltrichloroethane; DNP-SG, dinitrophenyl-S-gluta-
thione; EE, ethynylestradiol; EHBR, Eisai hyperbilirubinemic rats; ER, erucin; ERβ, estrogen
receptor β; FXR, farnesoid X-activated receptor; GNT, genistein; GY, Groningen Yellow; GSH,
glutathione; GST, glutathione S-transferase; HNFs, hepatic nuclear factors; IGF-1R, insulin-
like growth factor receptor 1; IL-6, interleukin 6; Keap1, Kelch-like ECH-associated protein 1;
L0, linker segment 0; LXRα, liver X receptor α; MAPK, mitogen-activated protein kinases; MRP,
multidrug resistance-associated protein; MRP2, multidrug resistance-associated protein 2;
hMRP2, human MRP2; rMrp2, rat Mrp2; mMrp2, mouse Mrp2; cMrp2, chickenMrp2; MSDs,
membrane-spanning domains; MTX, methotrexate; NAPQI, N-acetyl-p-benzoquinone imine;
NBDs, nucleotide-binding domains; NO, nitric oxide; Nrf2, nuclear factor-erythroid 2- related
factor-2; PhIP, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; PI3K, phosphoinositide 3-
kinase; PPARα, peroxisome proliferator activated receptor alpha; PXR, pregnane X receptor;
RARα, retinoic acid receptor α; RES, resveratrol; RXRα, retinoid X receptor α; SF, sulforaphane;
SL, spironolactone; SULT, sulphotransferase; TLR4, tool-like receptor 4; UGT, UDP-glucuro-
nosyltransferase.
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